These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24482120)

  • 41. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
    Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM
    Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
    Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
    J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.
    Greenbaum L; Israeli-Korn SD; Cohen OS; Elincx-Benizri S; Yahalom G; Kozlova E; Strauss H; Molshatzki N; Inzelberg R; Spiegelmann R; Israel Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2013 Nov; 19(11):1053-6. PubMed ID: 23932063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Pont-Sunyer C; Tolosa E; Caspell-Garcia C; Coffey C; Alcalay RN; Chan P; Duda JE; Facheris M; Fernández-Santiago R; Marek K; Lomeña F; Marras C; Mondragon E; Saunders-Pullman R; Waro B;
    Mov Disord; 2017 May; 32(5):726-738. PubMed ID: 28370517
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biochemical and pathological characterization of Lrrk2.
    Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM
    Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2.
    Estanga A; Rodriguez-Oroz MC; Ruiz-Martinez J; Barandiaran M; Gorostidi A; Bergareche A; Mondragon E; Lopez de Munain A; Marti-Masso JF
    Parkinsonism Relat Disord; 2014 Oct; 20(10):1097-100. PubMed ID: 25127457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins.
    Munhoz RP; Wakutani Y; Marras C; Teive HA; Raskin S; Werneck LC; Moreno D; Sato C; Lang AE; Rogaeva E
    Mov Disord; 2008 Jan; 23(2):290-4. PubMed ID: 17999435
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia.
    Saunders-Pullman R; Lipton RB; Senthil G; Katz M; Costan-Toth C; Derby C; Bressman S; Verghese J; Ozelius LJ
    Neurosci Lett; 2006 Jul; 402(1-2):92-6. PubMed ID: 16632201
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls.
    Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
    Neurobiol Aging; 2015 Feb; 36(2):1105-9. PubMed ID: 25475535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intact working memory in non-manifesting LRRK2 carriers--an fMRI study.
    Thaler A; Helmich RC; Or-Borichev A; van Nuenen BF; Shapira-Lichter I; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T; Mirelman A;
    Eur J Neurosci; 2016 Jan; 43(1):106-12. PubMed ID: 26536050
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.
    Vermilyea SC; Emborg ME
    Stem Cells Dev; 2018 Jul; 27(14):960-967. PubMed ID: 29402177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.
    Alcalay RN; Mejia-Santana H; Tang MX; Rosado L; Verbitsky M; Kisselev S; Ross BM; Louis ED; Comella CL; Colcher A; Jennings D; Nance MA; Bressman S; Scott WK; Tanner C; Mickel SF; Andrews HF; Waters CH; Fahn S; Cote LJ; Frucht SJ; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Marsh L; Hiner B; Siderowf A; Caccappolo E; Ottman R; Clark LN; Marder KS
    Arch Neurol; 2009 Dec; 66(12):1517-22. PubMed ID: 20008657
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
    Kumari U; Tan EK
    FEBS J; 2009 Nov; 276(22):6455-63. PubMed ID: 19804413
    [TBL] [Abstract][Full Text] [Related]  

  • 55. G2019S mutation of the leucine-rich repeat kinase 2 gene in a cohort of Egyptian patients with Parkinson's disease.
    Hashad DI; Abou-Zeid AA; Achmawy GA; Allah HM; Saad MA
    Genet Test Mol Biomarkers; 2011 Dec; 15(12):861-6. PubMed ID: 21699405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2.
    Hernandez DG; Paisán-Ruíz C; McInerney-Leo A; Jain S; Meyer-Lindenberg A; Evans EW; Berman KF; Johnson J; Auburger G; Schäffer AA; Lopez GJ; Nussbaum RL; Singleton AB
    Ann Neurol; 2005 Mar; 57(3):453-6. PubMed ID: 15732108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. LRRK2 G2019S in the North African population: a review.
    Benamer HT; de Silva R
    Eur Neurol; 2010; 63(6):321-5. PubMed ID: 20413974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.
    Ishihara L; Warren L; Gibson R; Amouri R; Lesage S; Dürr A; Tazir M; Wszolek ZK; Uitti RJ; Nichols WC; Griffith A; Hattori N; Leppert D; Watts R; Zabetian CP; Foroud TM; Farrer MJ; Brice A; Middleton L; Hentati F
    Arch Neurol; 2006 Sep; 63(9):1250-4. PubMed ID: 16966502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fighting the risk of developing Parkinson's disease; clinical counseling for first degree relatives of patients with Parkinson's disease.
    Giladi N; Mirelman A; Thaler A; Bar-Shira A; Gurevich T; Orr-Urtreger A
    J Neurol Sci; 2011 Nov; 310(1-2):17-20. PubMed ID: 21704337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy.
    Yakhine-Diop SM; Bravo-San Pedro JM; Gómez-Sánchez R; Pizarro-Estrella E; Rodríguez-Arribas M; Climent V; Aiastui A; López de Munain A; Fuentes JM; González-Polo RA
    Toxicology; 2014 Oct; 324():1-9. PubMed ID: 25017139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.